188 related articles for article (PubMed ID: 29632007)
21. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
[TBL] [Abstract][Full Text] [Related]
22. Treatment of PTLD with rituximab or chemotherapy.
Elstrom RL; Andreadis C; Aqui NA; Ahya VN; Bloom RD; Brozena SC; Olthoff KM; Schuster SJ; Nasta SD; Stadtmauer EA; Tsai DE
Am J Transplant; 2006 Mar; 6(3):569-76. PubMed ID: 16468968
[TBL] [Abstract][Full Text] [Related]
23. Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation.
Gifford G; Fay K; Jabbour A; Ma DD
Intern Med J; 2015 May; 45(5):583-6. PubMed ID: 25955465
[TBL] [Abstract][Full Text] [Related]
24. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.
Patrick A; Wee A; Hedderman A; Wilson D; Weiss J; Govani M
J Neurooncol; 2011 Jul; 103(3):739-43. PubMed ID: 20872273
[TBL] [Abstract][Full Text] [Related]
25. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
26. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).
García-Cadenas I; Yáñez L; Jarque I; Martino R; Pérez-Simón JA; Valcárcel D; Sanz J; Bermúdez A; Muñoz C; Calderón-Cabrera C; García E; Alonso L; Suárez-Lledó M; González Vicent M; Heras I; Viguria MC; Batlle M; Vázquez L; López J; Solano C;
Eur J Haematol; 2019 Jun; 102(6):465-471. PubMed ID: 30828868
[TBL] [Abstract][Full Text] [Related]
27. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
[TBL] [Abstract][Full Text] [Related]
28. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
29. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
Cavaliere R; Petroni G; Lopes MB; Schiff D;
Cancer; 2010 Feb; 116(4):863-70. PubMed ID: 20052713
[TBL] [Abstract][Full Text] [Related]
30. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.
Roychowdhury S; Peng R; Baiocchi RA; Bhatt D; Vourganti S; Grecula J; Gupta N; Eisenbeis CF; Nuovo GJ; Yang W; Schmalbrock P; Ferketich A; Moeschberger M; Porcu P; Barth RF; Caligiuri MA
Cancer Res; 2003 Mar; 63(5):965-71. PubMed ID: 12615710
[TBL] [Abstract][Full Text] [Related]
31. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus.
Hierro L; Díez-Dorado R; Díaz C; De la Vega A; Frauca E; Camarena C; Muñoz-Bartolo G; González de Zárate A; López Santamaría M; Jara P
Liver Transpl; 2008 Aug; 14(8):1185-93. PubMed ID: 18668670
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; Capote FJ; Gómez-Codina J; Panizo C; Salar A; Sancho JM; López A; Briones J; Muñoz A; Encuentra M; Mercadal S; Domingo-Domenech E; de Sevilla AF;
Ann Hematol; 2021 Apr; 100(4):1023-1029. PubMed ID: 32367180
[TBL] [Abstract][Full Text] [Related]
34. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
36. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-immunotherapy.
Inoue H; Rai S; Tanaka H; Espinoza JL; Komori-Inoue M; Kakutani H; Minamoto S; Kumode T; Nakayama S; Taniguchi Y; Morita Y; Okuda T; Tatsumi Y; Ashida T; Matsumura I
Viruses; 2020 Apr; 12(4):. PubMed ID: 32276450
[TBL] [Abstract][Full Text] [Related]
38. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
39. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
Banks CA; Meier JD; Stallworth CR; White DR
Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
[TBL] [Abstract][Full Text] [Related]
40. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
Montone KT; Hodinka RL; Salhany KE; Lavi E; Rostami A; Tomaszewski JE
Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
